## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per recogness:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					or	Sect	ion 30	O(h) of the I	nvestmen	t Cor	npany Act o	of 1940							
1. Name and Address of Reporting Person*  DIXON WENDY L  (Last) (First) (Middle)  60 BINNEY STREET					2. Issuer Name <b>and</b> Ticker or Trading Symbol bluebird bio, Inc. [ BLUE ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
				3. Date of Earliest Transaction (Month/Day/Year) 11/11/2021										r (give title		Other (specify below)			
(Street) CAMBRIDGE MA 02142				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person							
(City) (State) (Zip)														reisuii					
		Та	ble I - Non			_				Dis	1			ly Owned					
1. Title of Security (Instr. 3)			Date	. Transaction tate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (		Disposed	ies Acquire Of (D) (Ins		Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	٧	Amount	(A) or (D)	File	(Instr. 3 a	rsaction(s) tr. 3 and 4)		<u> </u>			
Common	Stock <sup>(1)(2)(3</sup>		T-51- 11 F	11/11					J		6,241		\$(		894		D		
			Table II - [								osea of, onvertib			/ Owned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Cod	ansaction Der ode (Instr. Sec Acc or I of (		Deri Seci Acq or D	umber of vative urities uired (A) isposed D) (Instr. 3, d 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title ar of Securi Underlyir Derivative (Instr. 3 a	ties ig e Security	Derivative Security	derivative Securities Beneficiall Owned Following Reported	Owne Form: Direct or Ind	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Co	de '	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amoun or Numbe of Shares		Transaction(s) (Instr. 4)				
Stock Option (right to buy)	\$4.07 <sup>(4)</sup>	11/11/2021		J				26,361 <sup>(4)</sup>	(4)		04/29/2023	Common Stock	25,95	3 \$0	25,953		D		
Stock Option (right to buy)	\$12.54 <sup>(5)</sup>	11/11/2021		J				7,500 <sup>(5)</sup>	(5)		06/11/2024	Common Stock	7,384	\$0	7,384		D		
Stock Option (right to buy)	\$92.14 <sup>(6)</sup>	11/11/2021		J				7,500 <sup>(6)</sup>	(6)		06/04/2025	Common Stock	7,384	\$0	7,384	4	D		
Stock Option (right to buy)	\$23.85 <sup>(7)</sup>	11/11/2021		J				4,000 <sup>(7)</sup>	(7)		06/02/2026	Common Stock	3,938	\$0	3,938		D		
Stock Option (right to buy)	\$55.29 <sup>(8)</sup>	11/11/2021		J				4,000 <sup>(8)</sup>	(8)		06/08/2027	Common Stock	3,938	\$0	3,938	3	D		
Stock Option (right to buy)	\$91.2 <sup>(9)</sup>	11/11/2021		J				4,000 <sup>(9)</sup>	(9)		06/20/2028	Common Stock	3,938	\$0	3,938	3	D		
Stock Option (right to buy)	\$60.78 <sup>(10)</sup>	11/11/2021		J				4,000 <sup>(10)</sup>	(10)		06/06/2029	Common Stock	3,938	\$0	3,938	3	D		
Stock Option (right to buy)	\$31.93 <sup>(11)</sup>	11/11/2021		J				3,000 <sup>(11)</sup>	(11)		06/18/2030	Common Stock	2,953	\$0	2,953	3	D		
Stock Option (right to	\$16.36 <sup>(12)</sup>	11/11/2021		J				5,000 <sup>(12)</sup>	(12)		06/15/2031	Common Stock	10,03	8 \$0	10,03	8	D		

### **Explanation of Responses:**

<sup>1.</sup> Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders.

<sup>2.</sup> bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").

<sup>3.</sup> bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP.

- 4. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on April 29, 2013 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 5. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 11, 2014 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 6. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 4, 2015 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 7. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 2, 2016 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 8. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase sheepens adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 9. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 10. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 11. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested and exercisable as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and
- 12. Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3.

\*\*Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

> 11/17/2021 /s/ Helen Fu. Attorney-in-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.